Support our fight against COVID-19
The FLCCC needs your support to continue and expand its education and lobbying efforts to educate and share the latest information on effective treatments of COVID-19 patients while the vaccine is being distributed.
Your donations will help support the FLCCC Alliance with the rising costs of public relations, research, medical education, translation, advocacy, and lobbying.
Thank you for your help! And to all of our thoughtful contributors, we want you to know how grateful we are to you for recognizing and so generously supporting the urgency and importance of our work. We wish you a lifetime of good health.
The Front Line Covid-19 Critical Care Alliance (FLCCC Alliance) is a 501c3 non-profit organization* founded in March 2020 with the simple goal of developing the most effective treatment protocols possible for COVID-19 patients. Our approach is based on the use of outcome-based medicine by repurposing existing drugs to minimize fatalities and reduce long-term effects in patients suffering from this pandemic.
Our founding members are highly published critical care specialists from major academic medical centers with nearly 2,000 medical publications and numerous major contributions to the field of medicine.
- Watch Dr. Pierre Kory’s Dec 8, 2020 US senate hearing on our Official Testimony page.
- Watch Dr. Pierre Kory’s statements on the effectiveness of ivermectin in the latest data from international studies: Dr. Kory interviewed by Charles Groenhuijsen, Vincent Everts, Dr. Adam Cohen, Professor of Clinical Pharmacology at Leiden University and GP Walter Schrader which used to work in the tropics.
As the pandemic takes its toll on countries and economies worldwide, most governments have focused on vaccine development and vaccine distribution to beat COVID-19.
Thousands of people are suffering and dying while the vaccine is being produced and distributed. It will take months before we reach herd immunity through the vaccine and extended lockdowns may cause immeasurable long-term harm to our economies.
The FLCCC has identified 2 effective therapy protocols that can help slow down the pandemic to alleviate the current burden on our healthcare system and save lives at the same time:
- MATH+ — a combination therapy intended for the hospitalized patient and consisted of the core therapies of methylprednisolone, ascorbic acid, thiamine, and heparin, all delivered intravenously along with multiple adjunctive medicines
- I-MASK+ — a prophylactic and early treatment protocol centered around the use of ivermectin, a historically important medicine that has already won the Nobel Prize in medicine for its global impact in ridding the world of parasitic diseases and that shows promising anti-viral and anti-inflammatory properties against COVID-19
How else can you support the FLCCC Alliance
- Download and share our MATH+ and I-MASK+ life-saving protocols to your family, friends and doctors.
- Write to your elected officials to review our latest analyses, particularly on the repurposing of ivermectin to fight COVID-19.
- If you, your friend or family has benefited from the MATH+ or I-MASK+ protocols, post a testimonial of your experience on social media or send us an email.
- If your doctor prescribed you ivermectin or any other effective treatments to help fight COVID-19, contact us and connect us to your doctor so we can further study what works and what doesn’t.
January 14, 2021 – Good News – NIH allows ivermectin as a COVID-19 treatment!
Our latest meta-analysis of current international studies is showing mounting evidence that ivermectin can be highly effective in reducing transmission, hospitalization, and death in COVID-19.
- Pierre Kory presented the latest data on ivermectin to the NIH COVID-19 Treatment Guideline committee on Jan 6, 2021 (see our Press Release from Jan 7, 2021), and on Jan. 14, 2021, the NIH removed its recommendation against the use of ivermectin to treat COVID-19, giving ivermectin the same status – neither for nor against its use in COVID treatment – as experimental convalescent plasma and monoclonal antibodies (see our Press Release from Jan 7, 2021 and our Answer to the NIH statement from Jan 18, 2021).
- Andrew Hill, a PhD Senior Visiting Research Fellow in the Department of Pharmacology at the University of Liverpool, is soon to present his own analysis of the effectiveness of ivermectin to the WHO by the end of Jan 2021 as part of his work for Unitaid.
*The FLCCC Alliance has been incorporated in the State of Delaware and received 501(c)3 federal tax-exempt status as a public charity [Status: 170(b)(1)(A)(vi); Employer ID number: 85-2270146]. You can download the Determination Letter (IRS) here.
To learn more about our work, please go to About the FLCCC Alliance, there you will also find our Mission Statement and Objectives.